20th - 22nd April 2021 I Virtual Summit | 09.00 - 17.30 CEST

Europe NEOANTIGEN Summit

Weaponising Truly Individualised Therapies



Supercharge the engineering of personalized neoantigen and shared antigen vaccines and cell based immunotherapies through robust prediction, enhanced identification and critical validation

Andrew Allen
CEO
Gritstone Oncology

Jennie Lill
Executive Director of Proteomics & NGS
Genentech

Sijme Zeilemaker
COO
Immunicum

Wigard Kloosterman
CSO
Frame Cancer Therapeutics

Agnete Fredriksen
President & CSO
Vaccibody

Wim Van Criekinge
CSO
myNEO

Kostas Kosmatopoulos
CEO
Vaxon Biotech

Nicola Ternette
Head of Immunopeptidomics
University of Oxford

Proud to Partner with:

NEC NEC OncoImmunity AS · Personalis · GenScript Make Research Easy · ALMAC · Cayman Chemical · CEM We Simplify Science · GYROS PROTEIN Technologies · PathoQuest · PEPSCAN · Provepharm Life Solutions

Welcome to the 4th Annual Neoantigen Summit Europe

Your comprehensive end to end guide to creating truly personalized neoantigen vaccines & cell-based immunotherapies.

As the initial neoantigen clinical data proves to be lack luster there are critical questions that are unfolding that we need to answer to ensure continued therapeutic success.

The **Neoantigen Summit Europe** is the only industry-led meeting dedicated to the robust prediction, identification and validation of neoantigens to develop potent tumorigenic immune responses.

Join over 150 of the leading trailblazers in the neoantigen space such as **Gritstone Oncology**, **BioNtech**, **Genocea**, **3T Biosciences** and **Genentech**, to take part in stimulating discussions around shared and personalized neoantigens and how to realise the potential for neoantigens to create truly individualized cancer therapeutics.

Navigate across two tracks of content from increasing precision of high quality neoantigen target identification using AI heuristics to investigating the different delivery platforms being used to induce potent immunogenic response.

Join the leading industry experts this April to be at the forefront of essential discussions on the future extension of the neoantigen discovery domain and the extrapolation capabilities of epitope prediction tools for infectious diseases such as COVID-19.

Your Checklist to Developing Next Generation Cancer Immunotherapies

01 Explore innovative computational bio-simulation techniques and other novel models used for neoantigen prediction with **University of Oxford** and **myNeo**

02 Supercharge the effective identification of neoantigens with **Abbvie**, **Vall d'Hebron Institute of Oncology** & **Genentech** by learning about the novel neoantigen discovery tools being used

03 Learn how pioneering companies are developing novel methods to weaponise neoantigens including biospecific antibodies, oncolotic viruses and self-assembling nanoparticles with **Gritstone**, **Avidea** and **Valo Therpaeutics**

04 Optimizing immune priming in neoantigen based cancer vaccines for enhanced efficacy of treatment with P**recision Biologics** and **Immunicum**

05 Address the important manufacturing considerations for both personalized neoantigen vaccines and cell-based therapy with **Vaximm** and **Genocea**

Digital Events: An Interactive Online Experience

Neoantigen Summit Europe is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the virtual summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:

Delegate Profile

Set up personalized profiles to easily identify the name, job title & company of other attendees

Stage Area

Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite

Sessions Area

Smaller groups can get together in this breakout area for panel discussions and other interactive sessions

Demo Area

Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer

Chat Rooms

Conect with your peers and start conversations with individuals or all attendees in private and public chatrooms

Speed Networking

This virtual networking session will connect you with other attendees to establish new industry contacts

What You Can Expect from a Digital Event:

Live Q&As with Speakers

Ask your burning questions directly to our expert speakers in real-time, just as you would at a physical conference

Audience Discussions

Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry

8+ Hours of Networking

Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions

Content Available Post-Event

On conclusion of the event, presentations will be made available to attendees where possible

If you have any other questions about the platform, please visit our **please visit our website**

WORLD-CLASS SPEAKER FACULTY

Hans-Peter Gerber
CEO & CSO
3T Biosciences

Gregory Potts
Senior Scientist
Abbvie

Maren Lang
Head of Bioinformatics Research & Development
BioNTech SE

Anne De Groot
CEO/CSO
EpiVax, Inc

Jens Kringelum
Director, Genomic Immuno-Oncology
Exaxion Biotech

Wigard Kloosterman
CSO
Frame Cancer Therapeutics

Hubert Lam
Director, Pre-clinical Development
Genocea

Pranay Khare
Director, Cell Therapy Development & Manufacturing
Genocea Biosciences

Jennie Lill
Executive Director of Proteomics & NGS
Genentech

Christopher Rose
Senior Scientist - Discovery Proteomics
Genentech

Raymond Miller
Senior Global Product Manager, Therapeutic Materials
GenScript Biotech Corporation

Andrew Allen
CEO
Gritstone

Gerben Zondag
CEO
Immunetune

Sijme Zeilemaker
COO
Immunicum

Lei Zheng
Professor
John Hopkins School of Medicine

Alexandre Harari
Group leader, Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Wim Van Criekinge
CSO
myNeo

Elisa Scarselli
CSO and Co-founder
Nouscom

Pia Kvistborg
Junior group leader, Department of Immunology
The Netherlands Cancer Institute

Trevor Clancy
CSO & Co-founder
NEC OncoImmunity

Maik Pruess
Senior Field Applications Scientist
Personalis

WORLD-CLASS SPEAKER FACULTY



Philip Arlen
CEO & CMO
Precision Biologics

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines
Transgene

Nicola Ternette
Head of Immunopeptidomics
University of Oxford

Russell Pachynski
Assistant Professor, Division of Oncology
Washington University School of Medicine

Tom Whitehead
Co-Founder
Emily Whitehead Foundation

Sara Mangsbo
Associate Professor, Co-Founder
Uppsala University Sweden, Strike Pharma AB

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

Alena Gros
Principal Investigator, Tumor Immunology & Immunotherapy
Vall d'Hebron Institute of Oncology (V.H.I.O)

Sari Pesonen
Head of R&D
Valo Therapeutics

Heinz Lubenau
Chief Executive Officer & Co-Founder
Vaximm

Kostas Kosmatopoulos
CEO
Vaxon Biotech

"The relevance of neoantigens in the clinical efficacy of immunotherapy is beyond doubt. However, several fundamental and practical questions remain unanswered and this meeting is an opportunity to discuss these issues with experts of the field."

Alexandre Harari, Group leader, Department of Oncology UNIL CHUV, **Ludwig Institute for Cancer Research, Lausanne**

FOCUS DAY | TUESDAY APRIL 20, 2021

This focus day aims to delve deep into the promise, the progress and the pitfalls related to weaponizing neoantigen cell-based immunotherapies. And with research tools that were previously used to guide antigen and epitope selection for anticancer agents now be used in the fight against Covid-19 too, the pandemic has forced a shift in mindset for some biotech towards developing vaccines for infectious disease. This focus day will explore methods taken to leverage current computational vaccine design technology for development of Covid-19 vaccines.

10.00 **Chairs Opening Remarks**

- Setting the Scene: Why choose Personalized Cell Therapy Over Personalized Vaccines?
- Quick introduction as to why neoantigen cell therapy is behind neoantigen vaccine development in terms of number of active clinical trials
- Why pioneers in this space believe that cell therapy will soon surpass vaccines
- The impact of Covid-19 on the cancer immunotherapy field

10.10 **Novel Strategies to Improve Personalized Neoantigen Discovery**

- Development of novel personalized T cell therapies for cancer treatment
- Optimizing neoantigen discovery: novel strategy to preselect candidate neoantigens; comparison of tandem minigene screens and peptide pool screens for neoantigen identification
- Identification of tumor-infiltrating and peripheral blood T cell subsets enriched for neoantigen recognition

Alena Gros
Principal Investigator, Tumour, Immunology & Immunotherapy
Vall d'Hebron Institute of Oncology (V.H.I.O)

10.40 **Delving into the Properties of T-Cell Recognized Neoantigens**

- Leveraging an in-silico prediction pipeline
- Identifying T cell recognized neoantigens
- Elucidating properties that may lead to T cell recognition
- How can we use this platform to help predict immunogenicity

Pia Kvistborg
Junior group leader, Department of Immunology
The Netherlands Cancer Institute

11.10 **Morning Refreshments & Group Networking**

11.40 **Leveraging the experience from development of individualized cancer vaccines to vaccines against infectious diseases, including pandemics using the Vaccibody platform technology**

- Targeting antigens to antigen presenting cells to generate more rapid, strong, broad and long-lasting responses
- Transferability of manufacturing considerations
- Weighing the importance of humoral versus cellular responses, including choice of antigens

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

12.10 **Computational Design of a Global Peptide-based COVID-19 vaccine for Variable Viral Strains and Variable Human Genetics**

- Validated strategy to optimize vaccines for individuals and populations instead of distinct HLA alleles, using in silico clinical trials of real subjects
- Safety and immunogenicity of PolyPEPI-SCoV-2 in 2 mouse models
- How a cocktail of 9 peptides mimics the diversity of T cell responses induced by natural SARS-CoV-2 infection
- Extrapolation of findings in COVID-19 convalescent subjects to 16,000 HLA-genotyped subjects with 16 different ethnicities

Eniko Toke
CSO
Treos Bio

12.50 **Lunch**

13.50 **Building on Experience: A T cell epitope-driven COVID-19 Vaccine using the iVAX Platform**

- Fast, safe, and effective: T cell epitope driven vaccines
- Power of iVAX toolkit and Rationale for pivot to COVID-19
- Current Plans for safety and immunogenicity studies

Anne De Groot
CEO/CSO
EpiVax, Inc

14.20 **FLOVID-20: A Targeted T-cell Immunotherapy for COVID-19 using a Nebulizer**

- Microsphere technology encapsulates peptides and adjuvant for inhaled delivery to stimulate the immune system towards SARS-CoV-2.
- Non-human primates vaccinated via inhalation were shown to have an immune response towards SARS-CoV-2 nucleoprotein, leading to protection against COVID-19.

Scott Burkholz
Bioinformatics Scientist
Flow Pharma, Inc.

14.50 **Designing Best in Class TCR Cell Therapies Against Novel Antigens**

- Identifying the nuances of neoantigen TCR-based therapies to allow acceleration to the clinic
- Importance of diversity for identifying first in class targets and best in class T cell receptors while minimizing off-target toxicity
- Characterizing T cell receptors with the ideal binding profile.
- Utilization of a mass spectrometry independent yeast display platform that leverages in silico based prediction models to de-risk T cell receptor cell therapies.

Hanspeter Gerber
CEO and CSO
3T Biosciences

15.20 **Engineered T cells for the Treatment of Malignancy**

- Challenges with current therapeutic modalities, and why engineered T cell therapeutics are an attractive option.
- Challenges and improvements to in silico based prediction methods for selecting epitopes for generating TCRs against.
- Current strategy for selecting epitopes for engineering T cells against using a combination of biochemical and mass spectrometric approaches.

Jennie Lill
Executive Director of Proteomics & NGS
Genentech

14.50 **Closing Remarks**

16.00 **End of Focus Day**

8.30 **Chair's Opening Remarks**

Eric Halioua
Président & CEO
PDC*line Pharma

Driving Discovery of Shared Neoantigens to Accelerate Development of Off-the-Shelf Cancer Vaccines

8.45 **Whole Framome Cancer vaccination**

- Discovery of the full potential of frameshift neoantigens as targets of cancer immunotherapy
- Personalized cancer immunotherapy using Framome neoantigen vaccines

Wigard Kloosterman
Chief Scientific Officer
Frame Cancer Therapeutics

9.15 **A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared Neoantigen-Based Personal Vaccines**

- Vaccine design approach for two types of personal vaccines, off-the-shelf with candidate CDx and personalized: leveraging Cancer Testis Antigens as nonmutated neoantigens
- Data reveal from phase I/II clinical trial with PolyPEPI1018 off the shelf vaccine against MSS mCRC – unprecedented immunogenicity and initial efficacy
- Improved selection of Personal Epitopes (PEPIs) that induce predictable cytotoxic T cell responses - exploring our personalised cancer vaccines proof of concept study
- How this technology leads to a shorter needle-to-needle time and a more scalable product

Eniko R Toke
Chief Scientific Officer
Treos Bio

9.45 **An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens**

- Outline a high-performing machine learning approach, trained on mass spectrometry data, that predicts naturally processed and presented antigens
- Demonstrate how the predictor is integrated with several immune parameters, such HLA binding, in a deep learning layer to predict bona fide neoantigens
- Illustrate it's application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy

Trevor Clancy
CSO & Co-founder
NEC Oncoimmunity

10.15 **Virtual Speed Networking**

Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections

10.45 **Morning Refreshments**

CONFERENCE DAY ONE | WEDNESDAY APRIL 21, 2021

PREDICTION & IDENTIFICATION

Distinguishing Novel Neoantigen Discovery Tools for Development of Potent Tumorigenic Immune Responses

11.15 **Driving Antigen Discovery in Cervical Cancer**

- Evaluating how personalised genome or transcriptome sequencing information is essential for neoantigen discovery using LC-MS technology
- RNAseq allows variant mapping and identification of cryptic antigens
- Pathogen-driven tumours harbour a range of so far unknown targetable, tumour-specific neoantigen

Nicola Ternette, Head of Immunopeptidomics, **University of Oxford**

11.45 **Past and future developments in the use of AI heuristics for successful neoantigen prediction**

- Overview of biological processes involved in neoantigen immunogenicity that are being approximated by using innovative computational biosimulation
- Describing the clinical importance of increasing the True Positive Rate by using AI heuristics
- Identification of missing datasets key to successful prediction , and which efforts are being taken in the landscape to overcome these.

Wim Van Criekinge, CSO, **myNEO**

12.15 **Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology**

- NeoAntigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge.
- Leveraging extensive peptide synthesis experience GenScript has developed
- NeoPreTM, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone.
- NeoPreTM can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript's many synthesis platforms
- This presentation will highlight how NeoPreTM identifies synthesis difficulty and review successful cases of difficult neoantigen peptide synthesis from several researchers

Raymond Miller, Senior Global Product Manager, Therapeutic Materials, **GenScript Biotech Corporation**

CLINICAL TRANSLATION & MANUFACTURING

Supercharging Induction of Anti-Tumor Response by Exploring Different Delivery Platforms for Neoantigen Vaccination

11.15 **Development of an optimized platform for production and efficacy of personalized DNA vaccines**

- Personalized cancer vaccines suffer from long lead times, high costs, and/or low immunogenicity.
- Immunetune developed a cell-free production platform that enables rapid and affordable manufacturing of DNA vaccines for individual use.
- Optimized vaccine design and a pyroptosis-inducing genetic adjuvant boost T cell priming and improve tumor control.

Gerben Zondag, CEO, **Immunetune**

11.45 **Leveraging Onocolytic Viruses to Develop a Flexible Neoantigen Delivery Platform**

- Proprietary PeptiCRAd synergistically combine next generation oncolytic viruses with tumor associated antigens to trigger unparalleled T-cell mediated anti-tumor immune response
- Platform-based delivery can accommodate shared tumor antigens or patient-specific neoantigens
- Viruses are the perfect adjuvant for tumor-specific antigen delivery
- PeptiCRAd is synergistic with standard-of-care checkpoint inhibitors

Sari Pesonen, Head of R&D, **Valo Therapeutics**

12.15 **Towards a Flexible Peptide Based Delivery Platform for data-driven Personalized Cancer Therapy**

- MHC/peptide off-rates can determine peptide pharmacokinetic properties, a risk for "naked" peptide-based neoantigen therapeutics
- A flexible delivery system must provide improved stability, delivery and adjuvant capacity to peptide-based vaccines
- The talk will address the need of a flexible and scalable platform to improve cross-presentation for the optimal CD8 T cell activation in a patient's body and present a novel platform that achieves this goal

Sara Mangsbo, Associate Professor, Co- Founder, **Uppsala University Sweden, Strike Pharma AB**

12.45 **Lunch**

Distinguishing Novel Neoantigen Discovery Tools for Development of Potent Tumorigenic Immune Responses

13.45 **Identify HLA Class I and Class II specific TCRs in Pancreatic Cancer for Individualized T Cell Therapy**

- Both HLA Class I and Class II epitope peptides were eluted from PDAC tumour tissue by using anti-pan HLA Class I antibody and anti-pan HLA Class II antibody, respectively, followed by mass spectrometry analysis. Approximately 20% eluted HLA Class I
- epitopes and Class II epitopes are overlapped
- TCRs for selected epitopes were cloned and their homologous TCR clones can be identified in the tumor infiltrating lymphocytes from PDAC tumour tissue.
- Antitumor activity of T cells engineered with the above cloned TCRs are tested

Lei Zheng, Professor, **John Hopkins School of Medicine**

14.15 **Disease-specific Immunopeptides for Generation of Soluble TCR Therapies**

- Patient tumor and healthy tissues were enriched for MHC class I peptides and identified by mass spectrometry
- Population prevalence was used to prioritize tumor-selective immunopeptides as candidate targets
- Soluble TCRs can be generated against disease-specific immunopeptides for development of targeted therapeutic strategies

Gregory Potts, Senior Scientist, **Abbvie**

14.45 11.45 **AI in personalized cancer medicine – recent improvements and next steps**

- Recent development in AI driven prediction tools to drive neoantigen clinical therapy
- AI identification of neo-antigens VS epitope discovery by assay based methods – Pros and cons
- Next steps – where do we get data for training improved methods

Jens Kringelum, Director, **Genomic Immuno-Oncology, Exaxion Biotech**

15.15 **Details to Be Confirmed**

Scott Burkholz,Bioinformatics Scientist, **Flow Pharma, Inc.**

15.45 **Pathoquest**

- Details to be Confirmed

Optimizing Immune Priming in Neoantigen Based Cancer Vaccines for Enhanced Efficacy of Treatment

13.45 **Self-assembling Nanoparticles Improve Peptide-based Neoantigen Vaccine Formulation Consistency & Immunogenicity**

- Self-assembling nanoparticles based on amphiphilic polymers (SNAP) enable consistent formulations with diverse peptide neoantigens
- SNAP delivering neoantigens combined with various adjuvants, e.g., agonists of TLR-3 (polyIC), TLR-7/8 (imidazoquinolines) and TLR-9 (CpG), leads to efficient T cell induction
- Consistent formulations that provide efficient T cell induction aid algorithm validation in vivo
- Combination therapies with SNAP vaccines that maximize T cell responses and efficacy

Geoffrey Lynn, CEO, **Avidea Technologies**

14.15 **Developing Novel Antibodies to Targeting Tumour Neoepitopes**

- Exploring a functional approach vs the classic predictive approach
- Evaluating different techniques of measuring immunogenicity
- Considerations towards scaling up and commercialization
- Preliminary clinical data from trials utilizing this approach

Philip Arlen, Chief Executive Officer, Chief Medical Officer, **Precision Biologics**

14.45 **Allogeneic Inflammatory Cells Indirectly Priming the Immune Response in the Patient's Tumor Tissue**

- Phase II data in RCC highlighting durable responses, complete responses and tail of the survival curve
- Ongoing Phase Ib combination study with checkpoint inhibitors in HNSCC, NSCLC and GA/GEJ
- Inflammatory cells producing chemokines and cytokines that recruit and activate patient's immune cells and indirectly priming neoantigen-specific CD8+ T cell response

Sijme Zeilemaker, Chief Operating Officer, **Immunicum**

15.15 **Does the Exquisite Tumor-Specificity of Neoantigens Render them Excellent Targets for Bispecific Antibody Therapy of Solid Tumors?**

- Bispecific antibodies are showing great promise in B cell malignancies where specific B cell markers offer good tumor targets
- Solid tumors have proven more challenging given lack of suitably tumor-specific targets
- Neoantigenic HLA-peptide complexes are highly tumor-specific and may provide good targets for TCR-mimetic antibody-based bispecific approaches

Andrew Allen, Co-founder, President and Chief Executive Officer, **Gritstone Oncology**

15.45 **Challenges in Peptide Manufacture Supporting Neoantigen-Derived Cancer Vaccines and How to Overcome Them**

- Challenges in enabling fast delivery of manufacturing peptides for individualised cancer vaccine therapies, within the required manufacturing controls
- How Almac has met the demands of the clinical research community and established itself as the world leading supplier in the field of neoantigen-derived peptides through its NeoPeptide™ platform
- Key factors that have enabled Almac to meet the manufacturing challenges

Alastair Hay, Head of Peptide Business and Process Development

15.55 **Afternoon Break**

16.15 **Personalis® NeXT Platform™ for High-Accuracy Neoantigen Prediction, Composite Biomarker Identification and Personalized Cancer Therapy Development**

- NEOPS™ (Neoantigen Presentation Score) combines the tumor genomic and immune-related analytics of the Personalis® NeXT Platform™ to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers.
- SHERPA™ (Systematic HLA Epitope Ranking Pan Algorithm) improves neoantigen presentation prediction compared to other in silico methods, and can enable more predictive biomarkers for cancer therapy as well as facilitate the development of neoantigen-targeting, personalized cancer therapies.
- NEOPS, SHERPA, and other recent enhancements to the company's HLA typing, HLA LOH detection and transcriptome analytics represent the latest update to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform™. Utilizing an augmented exome and transcriptome-based approach, NeXT enables the simultaneous analysis of both a tumor and its immune microenvironment from a single tumor specimen to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response.

Maik Pruess
Senior Field Applications Scientist
Personalis

16.45 **Personalized Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step**

- Typical solid tumork epithelial cells display class I HLA-presented neoantigens (not class II)
- Consistent priming of strong CD8+ T cell responses to these neoantigens is likely key to effective immunotherapy
- We will show phase one clinical and immunogenicity data from a heterologous prime-boost neoantigen immunotherapy program in solid tumor patients

Andrew Allen
Co-Founder, President & CEO
Gritstone Oncology

17.15 **Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic**

- What is the best neoantigen prediction platform?
- What is the most robust approach to identifying the "right" neoantigen?
- How to best deliver a neoantigen therapy, vaccine or cell therapy?
- What type of vaccine, cell based, DNA, RNA, Peptide?
- Which approach is safer and more efficacious?
- Should the focus be on shared neoantigens or private neoantigens?

Andrew Allen
Co-Founder, President & CEO
Gritstone Oncology

Hans-Peter Gerber
Co-Founder, President & CEO
3T Biosciences

17.45 **Chair's Closing Remarks**

18.00 **End of Day 1 of Neoantigen Summit**

Exploring Combination Therapy Approaches to Improve Clinical Efficacy of Neoantigen Therapeutics

8.50 **Chair's Opening Remarks**

Eric Halioua
Président & CEO
PDC*line Pharma

9.00 **Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression**

Nouscom Cancer vaccines targeting neoantigens:

- Rely on effective neoantigens prediction methods
- Can encode a large number of neoantigens
- Induce a robust neoantigens' specific CD4 and CD8 T cell immunity
- Cure large established tumours in mice when combined with checkpoint blockade

Elisa Scarselli
CSO and Co-founder
Nouscom

9.30 **Panel Discussion: Evaluating Combination Therapies**

- The hasty evolvement of combination strategies
- Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumor immune activity
- Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting
- Discuss regulatory pathway and limitations to approve two new drugs
- How to identify a clear biologic effect caused by combination
- Improving Clinical Efficacy through Immunotherapy Combinations

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

Heinz Lubenau
Chief Operating Officer & Co-Founder
Vaximm

Elisa Scarselli
CSO and Co-founder
Nouscom

10.00 **Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)**

- Differences and synergies between personalized/shared neoantigen identification, and target prediction for infectious diseases
- Exploration of different IO epitope prediction tools and their extrapolation capabilities for general infectious diseases
- Use case: designing an optimal construct for RNA-based SARS-CoV2 vaccine

Wim Van Criekinge
CSO
myNEO

10.30 **Morning Break**

CONFERENCE DAY TWO | THURSDAY APRIL 22, 2021

PREDICTION & IDENTIFICATION

Examining Binding Affinity of Neo-epitopes to Determine Cancer Vaccination Strategies

11.30 **High-affinity Neoepitope-Specific T Cells Accumulate in Tumours**

- NeoAg-specific CD8 T cells cover broad ranges of avidities (structural and functional)
- The structural avidity of neoAg-specific CD8 T cells is higher than that of TAA-specific CD8 T cells
- CD8 T cells bearing high avidity TCR better upregulate tumour-homing receptors,infiltrate tumour and control tumours

Alexandre HARARI, Group leader, Department of oncology UNIL CHUV, **Ludwig Institute for Cancer Research Lausanne**

12.00 **Characterizing Epitopes for Cancer Vaccines and T Cell Therapeutics**

- Update on current personalized cancer vaccine clinical approach, successes and challenges
- Basic research approaches to enhance presentation of neo-epitopes via various cellular perturbations
- Show casing some high throughput targeted spectrometric tools for further characterizing epitopes for binding affinity various HLA allele and presentation

Christopher Rose, Senior Scientist - Discovery Proteomics, **Genentech Inc.**

Identifying Novel Targets to Drive Development of Next Generation Cancer Vaccines

12.30 **Are Immunogenic Tumours the Best Targets of Tumour Vaccination?**

- Identifying the best targets for tumour vaccination
- Tumour infiltration and PDL1expression to identify the tumours that are more sensitive to vaccines
- Assessing non immunogenic tumours
- Outlining considerations for the future of neoantigens

Kostas Kosmatopoulos, CEO, **Vaxon Biotech**

CLINICAL TRANSLATION & MANUFACTURING

Addressing the Importance of Clinical Trial Design and Optimizing Lead Time to Accelerate Development of Neoantigen Therapies

11.30 **Designing the Right Clinical Trial for a Neoantigen Platform**

- Evaluation of options for clinical trial design
- How to define better clinical endpoints
- Considerations for in-house development and manufacturing vs outsourcing

Russell Pachynski, Assistant Professor, Division of Oncology; Faculty, Center for Human Immunology and Immunotherapy Centers (CHiiPs), **Washington University School of Medicine**

12.00 **Entering clinical trials with a personalized oral bacteria-based DNA vaccine - Overcoming hurdles and challenges**

- Selecting the neoantigen prediction technology
- Optimizing the manufacturing process to minimize the time to administration
- Ensuring compliance with regulatory requirements
- Designing the clinical study

Heinz Lubenau, Chief Operating Officer & Co-Founder, **Vaximm**

Overcoming the Technical Challenges of Personalised Therapy to Allow For Seamless Therapeutic Delivery

12.30 **Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy**

- Considerations for process design and specifications for a personalized neoantigen based vaccine and a personalized neoantigen based cell therapy.
- Approaches for dealing with human to human variability as well as process variability.
- Key supply chain considerations for ensuring supply of personalized product to the early phase clinical trials

Pranay Khare, Senior Vice President, Pharmaceutical Sciences & Manufacturing, **Genocea**

14.00 **TG4050 : Viral immunotherapy meets AI technology**

- TG4050 is based on a decade long expertise in designing viral vectors
- Viral immunotherapy constitutes a promising modality harnessing the natural sensitivity of immune system to virus to target cancer cells
- Viruses can be modified to alter their immunogenic properties and enhance anti-tumor activity
- A review of how different viruses can be combined to enhance immunogenicity and optimize lead time

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines
Transgene

13.00 **Lunch**

Clinical Case Studies & Critical Analysis of Current Data

This plenary session starts with precisely what the neoantigen field is striving for; clinical case studies. Hear from the most cutting-edge neoantigen clinical programs to date and evaluate the different clinical approaches.

- High level overview of the current state of play of neoantigens and a case study dive into the most promising clinical trials currently active
- Novel updates on clinical development of both personalized neoantigen vaccines and cell-based therapy

14.30 **The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre-Clinical Results**

- ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens
- Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity
- Be careful, common neoantigens may differ from common mutations
- The GEN-009 immunotherapy, designed with personalized ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009-101 Phase 1/2a clinical trial

Hubert Lam
Director, Pre-clinical Development
Genocea

15.00 **Session Details to be Confirmed**

Randy Sweis
Assistant Professor
University of Chicago

15.30 **Journey to CAR T-cell Therapy**

- Emily Whitehead's journey to become the first pediatric cancer patient to receive CAR T-cell therapy
- Establishing the Emily Whitehead Foundation to raise research funding and help more kids like Emily receive less toxic therapies
- A present day update on the Whitehead family, including news about their new book "Praying For Emily"

Tom Whitehead
Co-Founder
Emily Whitehead Foundation

16.00 **Chair's Closing Remarks**

Eric Halioua
Président & CEO
PDC*line Pharma

16.15 **End of Day 2 & Close of Neoantigen Summit**

PROUD TO PARTNER WITH

GET INVOLVED

Hugo Billyard
Senior Partnership Director
Tel: +44 203 141 8700
Email: sponsor@hansonwade.com

INDUSTRY DEVELOPMENT PARTNER:

NEC Oncoimmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy.
NEC Oncoimmunityis dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

www.oncoimmunity.com

EXPERTISE PARTNER:

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAPaccredited. For more information, please visit

www.personalis.com

PROGRAMME PARTNER:

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. GenScript's businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO (gene, peptide, protein, antibody services), enzyme and synthetic biology products, biologics development and manufacturing (Cell line development, leads discovery, leads generation and development), as well as cell therapy.

www.genscript.com

EXHIBITOR:

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personlised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

www.almacgroup.com

EXHIBITOR:

Cayman's Immunology and Cellular Metabolism Services can complement your drug discovery efforts. Our Immunopeptidome Profiling Services enable deep sequencing analysis of MHC associated peptides by LC-MS/MS, allowing neoantigen identification in cell lines and tumor tissue. Our Cellular Metabolism Services measure the metabolic response of cells to therapeutics under a wide range of customizable in vitro metabolic environments. Cayman's expertise in cell culture, immunoassays, antibodies, and assay development provides a complete solution for your research needs.

www.caymanchem.com

PROUD TO PARTNER WITH

GET INVOLVED

Hugo Billyard
Senior Partnership Director
Tel: +44 203 141 8700
Email: sponsor@hansonwade.com

CEM We Simplify Science

EXHIBITOR:

The Liberty PRIME is the absolute best system available for synthesizing peptides for per-sonalized medicine. The system is cGMP compliant with unmatched purity, speed, and effi-ciency for peptide production in batch quantities. No other peptide synthesizer even comes close to the PRIME's incredibly fast cycle times, with absolute minimum waste production. CEM Corporation has pioneered the use of microwave technology for peptide production since 2004 and remains the market leader in peptide synthesis instrumentation.

www.cem.com

GYROS PROTEIN Technologies

EXHIBITOR:

Gyros Protein Technologies AB is a leading provider of solutions for peptide synthesis and bioanalysis. Automated multi-channel peptide synthesizers from Gyros Protein Technologies are used in cGMP facilities for the rapid production of peptides for personalized medicine. Our focus is on helping scientists in industry and academia to increase productivity in research, drug discovery, preclinical and clinical development. The company combines the nanoliter-scale immunoassay expertise of Gyros with over three decades of instrument, manufacturing experience and scientific knowledge in peptide synthesis found in Protein Technologies. Gyros Protein Technologies is a division of Mesa Laboratories.

www.gyrosproteintechnologies.com

PathoQuest

EXHIBITOR:

Robust and efficient Quality Control testing is critical for the development of personalized cancer vaccines and immunotherapies in order to reduce time to market and improve patient outcomes. Developers, producers need QC testing which help de-risk their product development pipeline by preventing adventitious agent contamination and cell lines misidentification. To meet those objectives, PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process. This innovative approach allows for robust and unambiguous level of testing and for faster turnaround time.

www.pathoquest.com

PEPSCAN

EXHIBITOR:

Pepscan is able to guide and timely provide you with personalized neoantigen peptides of the highest quality for your clinical trial. We build on our role as critical partner in multiple personalized neoantigen peptide clinical trials and know what it takes to be a world-class partner in this area. Flexibility is an integral part of our GMP-graded state-of the art facility's workflows resulting in reliable delivery of neoantigen peptides in as little as three weeks.

www.pepscan.com/clinicalpeptide-services/personalizedmedicine

Provepharm Life Solutions

EXHIBITOR:

Provepharm Life Solutions is a pharmaceutical and a CDMO company commercializing immunopeptide services since 2003. Pionner in the chemical synthesis of + 100 mer long peptide we delivered our first clinical batch of a 96-mer peptide in 2006. Specialized in microgram therapies we have developed a one-stopshop offer for the delivery of ready to use peptide-based drug products including conjugates. For personalized peptide vaccine programs we designed a GMP manufacturing process to deliver up to 40 neoantigens every 6 weeks.

www.provepharm.com

WHY PARTNER:

The NeoAg Series provides the only end-to-end industry dedicated forum focused on the challenges faced by pharma, biotech, and academia looking to advance neoantigen targeting immunotherapies. Digital partnership with the Neoantigen Summit Europe will ensure you capitalise on the market share early, cement your position as an industry leader and support the growth in next-generation immunotherapies.

This is your opportunity to:

Maximize the 2:1 balance of live content and targeted online networking to **generate leads** and **build new relationships** with senior-level decision-makers from leading pharma and biotech companies.

Secure a branding or speaking opportunity to **demonstrate thought leadership, drive brand exposure** and differentiate yourself from competitors.

Secure a virtual exhibition booth to **showcase your expertise** and educate the industry on how you can support and streamline their efforts.

Delegate Seniority Breakdown



*Attendee breakdown from past Neoantigen series events

Total Breakdown of Audience by Industry



PREVIOUS ATTENDING COMPANIES

ACHILLES THERAPEUTICS, Aduro, ADVAXIS IMMUNOTHERAPIES, agenus, AMGEN, BioMotiv, BIONTECH, Bristol Myers Squibb, BrightPath Biotherapeutics, EVAXION, gritstone, gsk, immatics, ISA Pharmaceuticals, janssen, Kite Pharma, Lilly, MedImmune, MERCK, NEON THERAPEUTICS, nouscom, NOVARTIS, PACT pharma, Takeda, transgene, TREOS, TURNSTONE BIOLOGICS, VAXIMM

DIGITAL REGISTRATION

Team Discounts

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5+ delegates

For more information on group rates and eligibility criteria, please email info@hansonwade.com or visit the website.

Please select the correct ticket type at time of booking. Subject to organizer approval.

Academics are entitled to 30% off the industry price. For more information, email info@hansonwade.com.

*Drug Developer Pricing is reserved for pharmaceutical and biotech companies actively and publically developing neoantigen based therapeutics, that do not offer pay-for services.

** Please note: if you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. Email info@hansonwade.com for full T&Cs.

3 Easy Ways To Book

www.neoantigen-europe.com/take-part/register

Email: register@hansonwade.com

Tel: +44 203 141 8700

Top 3 Reasons to Attend

1 **Gain** the tools and insight you need to maximize the potential of your neoantigen therapeutic and advance your clinical pipeline

2 **Gain** an in-depth breakdown of the clinical landscape and technology innovations to advance your pipeline to successfully weaponize neoantigens for anti-tumor treatment

3 **Develop** long lasting connections with key senior industry leaders to accelerate the clinical and commercial development of your neoantigen based immunotherapies

Drug Developer Pricing*	Final Price
2 Day Conference + Focus Day	€ 2,598
2 Day Conference	€ 1,899
Focus Day Only	€ 799

Solution Provider Pricing	Final Price
2 Day Conference + Focus Day	€ 3,298
2 Day Conference	€ 2,399
Focus Day Only	€ 999